OTCMKTS:WINT - Windtree Therapeutics Stock Price, Price Target & More

$3.25 +0.20 (+6.56 %)
(As of 04/24/2018 08:49 AM ET)
Previous Close$3.05
Today's Range$3.07 - $3.25
52-Week Range$2.56 - $26.00
Volume3,800 shs
Average Volume2,583 shs
Market Capitalization$11.50 million
P/E RatioN/A
Dividend YieldN/A
Beta1.81

About Windtree Therapeutics (OTCMKTS:WINT)

Windtree Therapeutics logoWindtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company's technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company's core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.

Receive WINT News and Ratings via Email

Sign-up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolOTCMKTS:WINT
CUSIP25466840
Phone215-488-9300

Debt

Debt-to-Equity Ratio-0.63%
Current Ratio0.19%
Quick Ratio0.19%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.48 million
Price / Sales8.28
Cash FlowN/A
Price / CashN/A
Book Value($7.57) per share
Price / Book-0.43

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-18,440,000.00
Net Margins-1,227.48%
Return on EquityN/A
Return on Assets-289.28%

Miscellaneous

Employees29
Outstanding Shares3,770,000

How to Become a New Pot Stock Millionaire

Windtree Therapeutics (OTCMKTS:WINT) Frequently Asked Questions

What is Windtree Therapeutics' stock symbol?

Windtree Therapeutics trades on the OTCMKTS under the ticker symbol "WINT."

How were Windtree Therapeutics' earnings last quarter?

Windtree Therapeutics Inc (OTCMKTS:WINT) issued its earnings results on Monday, August, 21st. The biotechnology company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.99) by $0.23. The biotechnology company had revenue of $1.15 million for the quarter, compared to analyst estimates of $0.40 million. View Windtree Therapeutics' Earnings History.

Who are some of Windtree Therapeutics' key competitors?

Who are Windtree Therapeutics' key executives?

Windtree Therapeutics' management team includes the folowing people:
  • John R. Leone, Independent Chairman of the Board (Age 68)
  • Craig Fraser, President, Chief Executive Officer, Director (Age 51)
  • John A. Tattory, Chief Financial Officer, Senior Vice President (Age 49)
  • Mary B. Templeton Esq., Senior Vice President, General Counsel and Corporate Secretary (Age 68)
  • Kathryn A. Cole, Senior Vice President - Human Resources (Age 49)
  • Steven G. Simonson M.D., Senior Vice President and Chief Development Officer (Age 56)
  • William C. Roberts, Vice President - Investor Relations and Corporate Communications (Age 45)
  • Michael L. Magee, Vice President - Technical Operations (Age 54)
  • Mahady M. Joseph, Independent Director (Age 63)
  • Bruce A. Peacock, Independent Director (Age 65)

Has Windtree Therapeutics been receiving favorable news coverage?

Media headlines about WINT stock have been trending somewhat positive this week, according to Accern. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Windtree Therapeutics earned a daily sentiment score of 0.13 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 49.30 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of Windtree Therapeutics?

Shares of WINT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Windtree Therapeutics' stock price today?

One share of WINT stock can currently be purchased for approximately $3.25.

How big of a company is Windtree Therapeutics?

Windtree Therapeutics has a market capitalization of $11.50 million and generates $1.48 million in revenue each year. Windtree Therapeutics employs 29 workers across the globe.

How can I contact Windtree Therapeutics?

Windtree Therapeutics' mailing address is 2600 KELLY ROAD SUITE 100, WARRINGTON PA, 18976. The biotechnology company can be reached via phone at 215-488-9300 or via email at [email protected]


MarketBeat Community Rating for Windtree Therapeutics (WINT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  95 (Vote Outperform)
Underperform Votes:  81 (Vote Underperform)
Total Votes:  176
MarketBeat's community ratings are surveys of what our community members think about Windtree Therapeutics and other stocks. Vote "Outperform" if you believe WINT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe WINT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Windtree Therapeutics (OTCMKTS:WINT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Windtree Therapeutics in the last 12 months. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.002.002.002.50
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/A$8.00
Price Target Upside: N/AN/AN/A841.18% upside

Windtree Therapeutics (OTCMKTS:WINT) Consensus Price Target History

Price Target History for Windtree Therapeutics (OTCMKTS:WINT)

Windtree Therapeutics (OTCMKTS:WINT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
6/30/2017Stifel NicolausDowngradeBuy -> HoldView Rating Details
10/30/2016HC WainwrightSet Price TargetBuy$8.00View Rating Details
(Data available from 4/24/2016 forward)

Earnings

Windtree Therapeutics (OTCMKTS:WINT) Earnings History and Estimates Chart

Earnings by Quarter for Windtree Therapeutics (OTCMKTS:WINT)

Windtree Therapeutics (OTCMKTS WINT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2017Q3 2017($13.80)$0.02 millionViewN/AView Earnings Details
8/21/2017Q2 2017($0.99)($0.76)$0.40 million$1.15 millionViewN/AView Earnings Details
5/15/2017Q1 2017($1.37)$0.22 millionViewN/AView Earnings Details
3/31/2017Q4 2016($34.40)($15.40)$0.50 million$0.90 millionViewN/AView Earnings Details
11/14/2016Q3 2016($28.20)($20.00)$0.11 million$0.96 millionViewN/AView Earnings Details
8/10/2016Q2($1.64)($1.29)$0.08 million$0.11 millionViewN/AView Earnings Details
5/12/2016Q116($1.58)($1.70)$0.08 millionViewListenView Earnings Details
3/24/2016Q4($0.70)($1.26)$0.07 million$0.66 millionViewListenView Earnings Details
11/5/2015Q3 2015($11.20)($25.21)$0.48 million$0.07 millionViewN/AView Earnings Details
8/10/2015Q215($0.13)($0.13)$0.45 million$0.08 millionViewListenView Earnings Details
5/7/2015Q1 2015($28.01)($39.22)$0.56 million$0.19 millionViewN/AView Earnings Details
3/16/2015Q414($0.14)($0.12)$0.54 million$1.18 millionViewN/AView Earnings Details
11/6/2014($0.15)($0.13)$0.50 million$0.53 millionViewN/AView Earnings Details
8/5/2014Q2 14($0.15)($0.12)$0.26 million$1.09 millionViewN/AView Earnings Details
5/8/2014Q114($0.13)($0.14)$2.69 million$0.03 millionViewN/AView Earnings Details
3/13/2014Q413($0.16)($0.16)$0.36 million$0.0740 millionViewN/AView Earnings Details
11/12/2013Q3($0.20)($0.22)$0.11 million$0.06 millionViewListenView Earnings Details
8/8/2013Q2 2013($0.28)($0.18)$10.00 million$0.1820 millionViewN/AView Earnings Details
5/7/2013Q1 2013($75.63)($81.23)$0.07 millionViewN/AView Earnings Details
11/8/2012Q312($0.23)($0.31)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Windtree Therapeutics (OTCMKTS:WINT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Windtree Therapeutics (OTCMKTS WINT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.80%
Institutional Ownership Percentage: 0.03%
Insider Trading History for Windtree Therapeutics (OTCMKTS:WINT)
Institutional Ownership by Quarter for Windtree Therapeutics (OTCMKTS:WINT)

Windtree Therapeutics (OTCMKTS WINT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/4/2018Pharmaceutical Holdings Lee'sMajor ShareholderBuy541,667$4.80$2,600,001.60View SEC Filing  
10/28/2016Craig FraserInsiderBuy7,500$2.05$15,375.007,500View SEC Filing  
2/19/2013John R LeoneDirectorBuy3,000$2.88$8,640.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Windtree Therapeutics (OTCMKTS WINT) News Headlines

Source:
DateHeadline
Windtree Therapeutics Announces Closing of $2.6 Million Private PlacementWindtree Therapeutics Announces Closing of $2.6 Million Private Placement
finance.yahoo.com - April 12 at 9:21 AM
Windtree Therapeutics Inc (WINT) Major Shareholder Pharmaceutical Holdings Lees Purchases 541,667 SharesWindtree Therapeutics Inc (WINT) Major Shareholder Pharmaceutical Holdings Lee's Purchases 541,667 Shares
www.americanbankingnews.com - April 6 at 4:17 PM
Windtree Therapeutics (WINT) vs. DBV Technologies (DBVT) Head to Head SurveyWindtree Therapeutics (WINT) vs. DBV Technologies (DBVT) Head to Head Survey
www.americanbankingnews.com - April 2 at 1:16 PM
Financial Analysis: Windtree Therapeutics (WINT) and Puma Biotechnology (PBYI)Financial Analysis: Windtree Therapeutics (WINT) and Puma Biotechnology (PBYI)
www.americanbankingnews.com - March 21 at 7:20 PM
Reviewing Prothena (PRTA) and Windtree Therapeutics (WINT)Reviewing Prothena (PRTA) and Windtree Therapeutics (WINT)
www.americanbankingnews.com - March 17 at 7:24 PM
Financial Review: Windtree Therapeutics (WINT) and Mateon Therapeutics (MATN)Financial Review: Windtree Therapeutics (WINT) and Mateon Therapeutics (MATN)
www.americanbankingnews.com - March 16 at 12:31 PM
Windtree and Eleison Announce Collaboration to Explore Delivering Inhaled Lipid Cisplatin (ILC) Utilizing Windtrees Aerosol Delivery System (ADS)Windtree and Eleison Announce Collaboration to Explore Delivering Inhaled Lipid Cisplatin (ILC) Utilizing Windtree's Aerosol Delivery System (ADS)
finance.yahoo.com - March 12 at 6:13 PM
Analyzing Windtree Therapeutics (WINT) and Grifols SA, Barcelona (GRFS)Analyzing Windtree Therapeutics (WINT) and Grifols SA, Barcelona (GRFS)
www.americanbankingnews.com - February 22 at 7:28 PM
Windtree Therapeutics (WINT) Upgraded to "Sell" by ValuEngineWindtree Therapeutics (WINT) Upgraded to "Sell" by ValuEngine
www.americanbankingnews.com - February 4 at 8:54 AM
Critical Contrast: Windtree Therapeutics (WINT) & Jazz Pharmaceuticals (JAZZ)Critical Contrast: Windtree Therapeutics (WINT) & Jazz Pharmaceuticals (JAZZ)
www.americanbankingnews.com - January 19 at 3:14 PM
Analyzing Aevi Genomic Medicine (GNMX) and Windtree Therapeutics (WINT)Analyzing Aevi Genomic Medicine (GNMX) and Windtree Therapeutics (WINT)
www.americanbankingnews.com - January 8 at 1:30 AM
Windtree Therapeutics (WINT) and XOMA (XOMA) Critical SurveyWindtree Therapeutics (WINT) and XOMA (XOMA) Critical Survey
www.americanbankingnews.com - January 7 at 7:32 PM
Windtree Therapeutics to Provide AEROSURF® and Business UpdatesWindtree Therapeutics to Provide AEROSURF® and Business Updates
finance.yahoo.com - December 28 at 10:24 AM
Jazz Pharmaceuticals (JAZZ) & Windtree Therapeutics (WINT) Critical SurveyJazz Pharmaceuticals (JAZZ) & Windtree Therapeutics (WINT) Critical Survey
www.americanbankingnews.com - December 27 at 11:34 AM
Head-To-Head Survey: Windtree Therapeutics (WINT) and Trillium Therapeutics (TRIL)Head-To-Head Survey: Windtree Therapeutics (WINT) and Trillium Therapeutics (TRIL)
www.americanbankingnews.com - December 21 at 9:24 PM
Windtree Therapeutics Announces Reverse Stock SplitWindtree Therapeutics Announces Reverse Stock Split
finance.yahoo.com - December 21 at 4:25 PM
Windtree Therapeutics to Participate in Corporate Access Event in San Francisco, January 8 - 10, 2018Windtree Therapeutics to Participate in Corporate Access Event in San Francisco, January 8 - 10, 2018
finance.yahoo.com - December 13 at 10:57 AM
Head-To-Head Comparison: Windtree Therapeutics (WINT) versus SIGA Technologies (SIGA)Head-To-Head Comparison: Windtree Therapeutics (WINT) versus SIGA Technologies (SIGA)
www.americanbankingnews.com - December 11 at 5:38 AM
Windtree Therapeutics, Inc. :WINT-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017Windtree Therapeutics, Inc. :WINT-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 10:43 AM
Windtree Therapeutics Reports Third Quarter 2017 Financial ResultsWindtree Therapeutics Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 16 at 7:53 AM
Contrasting Windtree Therapeutics (WINT) & Its RivalsContrasting Windtree Therapeutics (WINT) & Its Rivals
www.americanbankingnews.com - November 14 at 5:28 PM

SEC Filings

Windtree Therapeutics (OTCMKTS:WINT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Windtree Therapeutics (OTCMKTS:WINT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Windtree Therapeutics (OTCMKTS WINT) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.